Ginkgo Bioworks Holdings, Inc. (DNA) stock
DNANYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/3013% below fair value
$8.44+0.12 (+1.44%)
Close on Nov 18, 2026Market cap $568.35MP/E –Yield –
Ginkgo Bioworks total assets
Total assets on the balance sheet at the end of each period.
Ginkgo Bioworks's total assets was $990.05M at Jun 30, 2026. For fiscal 2025 it was $1.12B, down 18.7% from the year before. The highest annual figure on record is $2.54B in fiscal 2022.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.12B | -18.7% |
| FY2024 | Dec 31, 2024 | $1.38B | -17.3% |
| FY2023 | Dec 31, 2023 | $1.67B | -34.4% |
| FY2022 | Dec 31, 2022 | $2.54B | +22.6% |
| FY2021 | Dec 31, 2021 | $2.07B | +206.7% |
| FY2020 | Dec 31, 2020 | $675.15M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $990.05M | -19.6% |
| Q1 FY2026 | Mar 31, 2026 | $1.03B | -20.1% |
| Q4 FY2025 | Dec 31, 2025 | $1.12B | -18.7% |
| Q3 FY2025 | Sep 30, 2025 | $1.19B | -19.7% |
| Q2 FY2025 | Jun 30, 2025 | $1.23B | -24.3% |
| Q1 FY2025 | Mar 31, 2025 | $1.29B | -18.2% |
| Q4 FY2024 | Dec 31, 2024 | $1.38B | -17.3% |
| Q3 FY2024 | Sep 30, 2024 | $1.48B | -26.9% |
| Q2 FY2024 | Jun 30, 2024 | $1.63B | -29.1% |
| Q1 FY2024 | Mar 31, 2024 | $1.58B | -34.6% |
| Q4 FY2023 | Dec 31, 2023 | $1.67B | -34.4% |
| Q3 FY2023 | Sep 30, 2023 | $2.03B | +8.3% |
| Q2 FY2023 | Jun 30, 2023 | $2.29B | +14.9% |
| Q1 FY2023 | Mar 31, 2023 | $2.42B | +17.5% |
| Q4 FY2022 | Dec 31, 2022 | $2.54B | +22.6% |
| Q3 FY2022 | Sep 30, 2022 | $1.87B | -13.0% |
| Q2 FY2022 | Jun 30, 2022 | $1.99B | +15.5% |
| Q1 FY2022 | Mar 31, 2022 | $2.06B | +19.1% |
| Q4 FY2021 | Dec 31, 2021 | $2.07B | +206.7% |
| Q3 FY2021 | Sep 30, 2021 | $2.15B | – |
| Q2 FY2021 | Jun 30, 2021 | $1.73B | – |
| Q1 FY2021 | Mar 31, 2021 | $1.73B | – |
| Q4 FY2020 | Dec 31, 2020 | $675.15M | – |
See a number that looks wrong?